Commentary: blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy

dc.creatorGómez Durán, Javier
dc.creatorEstrada Hormazábal, Manuel
dc.date.accessioned2018-09-06T13:50:14Z
dc.date.available2018-09-06T13:50:14Z
dc.date.created2018-09-06T13:50:14Z
dc.date.issued2018-04-19
dc.identifierFrontiers in Pharmacology Volumen: 9 Número de artículo: 381
dc.identifier10.3389/fphar.2018.00381
dc.identifierhttps://repositorio.uchile.cl/handle/2250/151505
dc.languageen
dc.publisherFrontiers Media SA.
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceFrontiers in Pharmacology
dc.subjectBimagrumab
dc.subjectActRIIA/B receptors
dc.subjectSkeletal muscle
dc.subjectAnabolic steroids
dc.subjectMyostatin/activin
dc.titleCommentary: blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución